Identification and functional analysis of novel thap1 mutations

ABSTRACT Mutations in _THAP1_ have been associated with dystonia 6 (DYT6). _THAP1_ encodes a transcription factor that represses the expression of _DYT1_. To further evaluate the mutational

spectrum of _THAP1_ and its associated phenotype, we sequenced _THAP1_ in 567 patients with focal (_n_=461), segmental (_n_=68), or generalized dystonia (_n_=38). We identified 10 novel

variants, including six missense substitutions within the DNA-binding Thanatos-associated protein domain (Arg13His, Lys16Glu, His23Pro, Lys24Glu, Pro26Leu, Ile80Val), a 1bp-deletion

downstream of the nuclear localization signal (Asp191Thrfs*9), and three alterations in the untranslated regions. The effect of the missense variants was assessed using prediction tools and

luciferase reporter gene assays. This indicated the Ile80Val substitution as a benign variant. The subcellular localization of Asp191Thrfs*9 suggests a disturbed nuclear import for this

mutation. Thus, we consider six of the 10 novel variants as pathogenic mutations accounting for a mutation frequency of 1.1%. Mutation carriers presented mainly with early onset dystonia

(<12 years in five of six patients). Symptoms started in an arm or neck and spread to become generalized in three patients or segmental in two patients. Speech was affected in four

mutation carriers. In conclusion, _THAP1_ mutations are rare in unselected dystonia patients and functional analysis is necessary to distinguish between benign variants and pathogenic

mutations. SIMILAR CONTENT BEING VIEWED BY OTHERS _IMPDH2_: A NEW GENE ASSOCIATED WITH DOMINANT JUVENILE-ONSET DYSTONIA-TREMOR DISORDER Article Open access 26 July 2021 IN-SILICO PHENOTYPE

PREDICTION BY NORMAL MODE VARIANT ANALYSIS IN _TUBB4A_-RELATED DISEASE Article Open access 07 January 2022 ALLELIC AND PHENOTYPIC HETEROGENEITY IN JUNCTOPHILLIN-3 RELATED NEURODEVELOPMENTAL

AND MOVEMENT DISORDERS Article Open access 06 April 2021 INTRODUCTION Dystonia is a movement disorder, characterized clinically by involuntary twisting, repetitive movements, and abnormal

postures.1 Mutations in the _THAP1_ (_THAP domain-containing, apoptosis-associated protein 1_) gene were identified to underlie dystonia 6 (DYT6), a form of primary torsion dystonia.2

_THAP1_ encodes a 213-amino acid transcription factor featuring a specific DNA-binding THAP (Thanatos-associated protein) zinc-finger domain at the N terminus and a nuclear localization

signal (NLS) towards the C terminus.2 We and others recently demonstrated _in vitro_ that the _DYT1_ promoter is a target for the transcription factor activity of THAP1.3, 4 Mutations in

_DYT1_ cause another form of primary torsion dystonia.5 About 50 different _THAP1_ mutations have been reported to date including missense, nonsense, and frameshift mutations.2, 6, 7, 8, 9,

10, 11, 12, 13, 14, 15, 16, 17 In addition to the disease-causing mutations, two variants, c.-237_236delinsTT and c.71+9C>A, in the non-coding region of _THAP1_ may be associated with

dystonia.9, 13 DYT6 typically manifests as early-onset generalized or segmental dystonia, frequently with prominent laryngeal involvement and a rostrocaudal evolution of symptoms.6, 7, 8, 9,

10, 11, 12, 13, 14, 15 The phenotype though is highly variable even within a single family ranging from unaffected carriers to generalized dystonia.8, 9, 13 Mutation frequency varies

between 0.5% in unselected primary dystonia patients13 and 25% in non-DYT1 multiplex families in whom at least one individual had non-focal involvement and onset of symptoms by < 22

years.7 The clinical relevance of some reported mutations in _THAP1_ is equivocal. Recently, _in-vitro_ tests have become available to explore the functional consequences of different

mutations.3, 4, 18 In the present study, we investigated 567 patients with primary dystonia for mutations in the _THAP1_ gene and performed an _in-vitro_ assay to assess the putative

functional consequences of the mutations. These findings were related to the clinical phenotype of mutation carriers. PATIENTS AND METHODS PATIENTS The study was approved by the local ethics

committee and all participants gave written informed consent. Since our initial study in 2009,9 we collected another 498 unrelated patients and included 69 patients who were tested in 2009

for known mutations only (published as Group B9 including patients with sporadic focal dystonia without facial or laryngeal involvement and onset >26 years). Patients were consecutively

recruited at different movement disorders centers including the Section of Clinical and Molecular Neurogenetics Lübeck, Germany, the General Hospital Kassel, Germany, the University

Hospitals of Hamburg-Eppendorf, Berlin (Charité), Rostock, and Kiel, the Institute of Music Physiology and Musicians’ Medicine, University of Music, Drama and Media, Hanover, the University

Hospital of Belgrade, Serbia, and the Toronto Western Hospital, Canada. All patients were examined by at least one movement disorder specialist. The diagnosis of primary dystonia was

established based on the absence of a history of neuroleptic exposure, head trauma, and anoxia and of any clinical symptoms or signs suggestive of secondary dystonia. Further, secondary

causes were excluded by brain MRI. Patients were of German (_n_=436), Serbian (_n_=120), or Canadian (_n_=12) origin. All patients tested negative for the GAG deletion in the _DYT1_ gene.

Patients presented mainly with focal dystonia (_n_=461; 81%). GENOTYPING To test for mutations, we sequenced all three exons and exon–intron boundaries of the _THAP1_ gene using a capillary

sequencing machine. Sequences were aligned to the reference sequence (NC_000008.10) using the Mutation Surveyor software (SoftGenetics, State College, PA, USA). In addition, the frequency of

two known polymorphisms and all novel missense variants were determined in 365 German controls by sequencing. To assess the effect of the missense mutations _in silico_, the prediction

softwares PolyPhen219 (HumVar- tool; http://genetics.bwh.harvard.edu/pph2/) and SIFT20 were used. MEASUREMENT OF TRANSCRIPTION FACTOR ACTIVITY We previously showed that THAP1 represses the

expression of _DYT1_ in a concentration-dependent manner and that DYT6-associated mutations result in decreased repression of _DYT1_ in Luciferase reporter gene assays.4 Here, we used these

reporter gene assays to characterize the novel missense mutations (Lys16Glu, Lys24Glu, Pro26Leu, Ile80Val) within the DNA-binding THAP domain in addition to the two previously tested

substitutions (Arg13His and His23Pro).4 In brief, human endothelial cells (HeLa) were transfected with wild-type or mutated THAP1 constructs in the pcDNA3.1/myc-his plasmid (Invitrogen,

Darmstadt, Germany) and the _DYT1_ core promoter fragment4 in the pGL4.10 vector (Promega, Mannheim, Germany) using FuGENE-HD (Roche, Mannheim, Germany). Activity of firefly and renilla

luciferase was measured after 24–48 h incubation with the Dual Luciferase Reporter Assay System (Promega) in a Mithras-Luminometer (Bertholdt, Bad Wildbach, Germany). All measurements were

verified in a minimum of three independent experiments and as triplicates in each experiment. SUBCELLULAR LOCALIZATION OF TRUNCATED THAP1 We investigated the subcellular localization of the

novel frameshift mutation c.570delA (Asp191Thrfs*9) that is downstream of the predicted NLS. The respective coding regions of wild-type and mutated _THAP1_ were inserted into the pEGFP-N3

plasmid (Clontech, Mountain View, CA, USA) to generate green fluorescent protein (GFP)-labeled THAP1 fusion proteins. These GFP-labeled constructs were transiently expressed for 48 h in

OVCAR-3 cells and localization was determined using confocal laser scanning microscopy as described.18 OVCAR-3 cells are well suited for immunocytochemistry experiments due to their size and

handling. RESULTS PATIENTS AND MUTATION SCREENING Clinical details of the patients are presented in Table 1. Among the 567 patients with primary dystonia, we identified 10 novel variants.

These included six missense substitutions within the DNA-binding THAP domain (Arg13His, Lys16Glu, His23Pro, Lys24Glu, Pro26Leu, Ile80Val), a 1-bp deletion resulting in a frameshift

downstream of the predicted NLS (Asp191Thrfs*9), a base pair substitution in the 5′ untranslated region (UTR; c.-32C>T), and two single base pair substitutions in a single patient in the

3′ UTR (c.*1A>G + c.*10A>T). Clinical and genetic information on mutation carriers is given in Table 2. A detailed case report including description of available family members has

been presented elsewhere for the patient with the Arg13His mutation.14 None of the novel substitutions was found among 730 German control chromosomes. In our sample, we identified the

c.-237_236delinsTT polymorphism only in the heterozygous state. Frequencies were comparable in patients and controls with 4.5% (in German patients), 5.0% (in Serbian patients), and 5.2% (in

controls). Frequencies of the variant for different subgroups of dystonia are shown in Table 3. The other polymorphism that was found more often among dystonia patients (8/1210) compared

with controls (1/400),13 c.71+9G>A, was present in 1/567 patients and in 1/365 controls. CHARACTERIZATION OF THE CODING VARIANTS In a first step, we performed an _in-silico_ analysis of

the newly identified non-synonymous variants. Using PolyPhen2, all but Lys24Glu and Ile80Val were predicted to have a possible (His23Pro) or probable (Arg13His, Lys16Glu, Pro26Leu) damaging

effect. The SIFT software, predicted an effect on protein function for five of the missense variants but not for Ile80Val (Table 2). As THAP1 regulates the expression of the _DYT1_ gene,4 we

used reporter gene assays as a readout of mutant THAP1 function. We analyzed the six missense variants within the DNA-binding THAP domain. THAP1 activity was most prominently reduced (80%)

for His23Pro, around 50% for Lys16Glu, Lys24Glu, and Pro26Leu, and about 20% for Arg13His. In our assay, the Ile80Val variant did not have any effect on the THAP1 activity (Figure 1; Table

2). To determine the effect of the Asp191Thrfs*9 frameshift mutation, we assessed its subcellular localization by confocal laser scanning microscopy. While wild-type THAP1–GFP fusion protein

was exclusively located in the nuclei, truncated THAP1 Asp191Thrfs*9 showed an impaired nuclear import and was also detected in the cytoplasm (Figure 2). For none of the samples with rare

variants in the non-coding regions, ie 5′ or 3′ UTR or intron 1, RNA was available to test for a potential effect on RNA stability or splicing. Affected family members were not available to

test for segregation of the variants. It was not possible to reveal whether the two substitutions in individual L4455 were located on the same chromosome. DISCUSSION We screened a group of

567 dystonia patients and identified 10 novel variants (1.8%), including six missense (1.1%) and a frameshift variant (0.2%). Based on functional analysis, we consider six of them (Arg13His,

Lys16Glu, His23Pro, Lys24Glu, Pro26Leu, Asp191Thrfs*9) to represent mutations, ie to be pathogenic (1.1%). The detected non-coding variants are unlikely to be pathogenic as they do not

affect the protein sequence. However, it is conceivable that they alter the expression efficiency but proof is lacking due to unavailability of the respective biological material such as RNA

or affected family members to test for segregation. The missense variant Ile80Val seems to represent a benign alteration as indicated by the remaining full THAP1 activity in the _in-vitro_

assay and as also calculated by both prediction tools. This finding is supported by three additional notions: first, the amino acids isoleucine and valine have a similar structure and both

belong to the unpolar amino acids. Second, Campagne _et al_21 revealed lysine 70 as the most C-terminal amino acid residue responsible for DNA binding by detailed structural determination of

the THAP domain. Thus, isoleucine 80 should not be involved in DNA binding. Third, the patient has a rather late age at onset (41 years) and speech is not affected (see below). On the other

hand, lack of an effect in the reporter gene assay might be specific to the tested target promoter or, alternatively, isoleucine 80 may be involved in another function of THAP1, such as

protein–protein interactions. THAP1 contains a bipartite NLS spanning 16 amino acids (aa 146–162) in the C-terminal part of THAP1.18 Although the frame-shift mutation Asp191Thrfs*9 does not

affect the NLS itself, we demonstrated an impaired nuclear import of mutant THAP1 _in vitro_. This altered intracellular distribution of THAP1 may be explained by a protein misfolding

affecting at least the C-terminal region of THAP1, which disturbs the formation of the bipartite NLS and results in a reduced interaction with nuclear importing proteins. Alternatively, it

is also conceivable that there is remaining THAP1 nuclear import and function _in vivo_ and the variant is benign. The DYT6-atypical phenotype in our patient with late onset (49 years) and

focal dystonia without involving speech actually supports this possibility. The results of prediction programs for functional effects of the mutations and the effect size measured _in vitro_

clearly correspond for four of the six missense changes including the Ile80Val variant. For Arg13His, however, an effect on function was predicted by both programs but experimental evidence

suggests a rather mild effect. The results for the Lys24Glu mutation were more conflicting as experimental evidence indicates a medium effect but one of the prediction programs (PolyPhen2)

predicted no functional change at all. We detected a THAP1 mutation in 1.1% of our mainly focal dystonia patients. Mutation frequency in the literature ranges from about 0.5–1.8% for mainly

unselected primary dystonia patients.9, 10, 11, 12, 13, 15 Thus, _THAP1_ mutations are rare in dystonia patients. About 50 different _THAP1_ mutations have been reported to date.2, 6, 7, 8,

9, 10, 11, 12, 13, 14, 15, 16, 17, 22 One-third of the mutations represents missense mutations located in the THAP domain and is thought to interrupt DNA binding. Another one-third of the

mutations are considered to disturb the NLS, such as nonsense mutations, small insertions/deletions, or missense mutations within the NLS. For these proteins, the nuclear import is disturbed

resulting in impaired transcriptional activity. Thus, in about 70% of the reported mutations, the DNA binding of mutant THAP1 is considered to be affected. However, functional proof for

most of the reported mutations is missing. In the present study, we show that the rare missense variant Ile80Val is probably not pathogenic. Regarding, the non-coding variants

c.-237_236delinsTT, we confirm that there is no significant association with dystonia. Interestingly, however, most studies demonstrate a higher (but not significantly higher) frequency of

the variant in dystonia patients compared with controls.9, 10, 23, 24 The association may occur only in subtypes of dystonia. To date, the total number of carriers is too small to obtain

significant differences for this rare variant. A differential effect in dystonia subtypes may also be the explanation for the lack of any trend in another study.11 In contrast to our study

design, these authors included only about 20% patients with focal dystonia and 75% of the patients had an age of onset <30 years.11 These inclusion criteria are likely to preferentially

select patients with monogenic causes of dystonia rather than those carrying polygenic risk factors, thereby masking a possible association. The c.71+9C>A was too rare in our sample to

evaluate any trend of a possible association with dystonia. Among the about 100 described mutation carriers, most presented with an early onset and cervical or arm dystonia at onset.6, 7, 8,

9, 10, 11, 12, 13, 14, 15 In more than 80% of the patients dystonia spreads to other body parts. Speech was affected in about 70% of patients. Clinical phenomenology in mutation carriers

reported here was similar. All had onset of symptoms in the neck or arm. All but one mutation carrier had an age at onset between 6 and 11 years and presented with generalized (_n_=3) or

segmental (_n_=2) dystonia. Only the carrier of the frameshift mutation close to the end of THAP1 had a late onset at the age of 49 years and dystonia remained focal for 10 years after

onset. It can be speculated that the effect of this mutation may be rather mild compared with the missense mutations as a considerable proportion of the protein can still enter the nucleus.

We also verified the high frequency of laryngeal involvement (4/6) ranging from mild spasmodic dysphonia to aphonia. Finally, we aimed to correlate the severity of missense changes in the

DNA-binding domain with clinical features. Interestingly, the carriers of the benign Ile80Val variant had a rather mild, DYT6-atypical phenotype with a late age at onset, focal dystonia,

normal speech, and a negative family history. Further, the carriers of the two mutations with the highest effect on protein function were the only two with a positive family history (Table

2), suggesting that these mutations may exhibit a higher penetrance. To date, these correlations are highly speculative and investigations of larger samples will reveal if _in-vitro_

functional analyses can be correlated to the phenotypic presentation. Taken together, we report 10 novel variants in _THAP1_ and demonstrate a functional effect for six of them, underlining

that functional analysis is necessary to distinguish between benign variants and pathogenic mutations. REFERENCES * Fahn S, Bressman SB, Marsden CD : Classification of dystonia. _Adv Neurol_

1998; 78: 1–10. Article  CAS  Google Scholar  * Fuchs T, Gavarini S, Saunders-Pullman R _et al_: Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. _Nat Genet_

2009; 41: 286–288. Article  CAS  Google Scholar  * Gavarini S, Cayrol C, Fuchs T _et al_: Direct interaction between causative genes of DYT1 and DYT6 primary dystonia. _Ann Neurol_ 2010; 68:

549–553. Article  CAS  Google Scholar  * Kaiser FJ, Osmanoric A, Rakovic A _et al_: The dystonia gene DYT1 is repressed by the transcription factor THAP1 (DYT6). _Ann Neurol_ 2010; 68:

554–559. Article  CAS  Google Scholar  * Ozelius LJ, Hewett JW, Page CE _et al_: The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. _Nat Genet_ 1997; 17: 40–48.

Article  CAS  Google Scholar  * Bonetti M, Barzaghi C, Brancati F _et al_: Mutation screening of the DYT6/THAP1 gene in Italy. _Mov Disord_ 2009; 24: 2424–2427. Article  Google Scholar  *

Bressman SB, Raymond D, Fuchs T, Heiman GA, Ozelius LJ, Saunders-Pullman R : Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study. _Lancet Neurol_ 2009; 8: 441–446.

Article  CAS  Google Scholar  * Clot F, Grabli D, Burbaud P _et al_: Screening of the THAP1 gene in patients with early-onset dystonia: myoclonic jerks are part of the dystonia 6 phenotype.

_Neurogenetics_ 2011; 12: 87–89. Article  Google Scholar  * Djarmati A, Schneider SA, Lohmann K _et al_: Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic

dysphonia: a genetic screening study. _Lancet Neurol_ 2009; 8: 447–452. Article  CAS  Google Scholar  * Groen JL, Ritz K, Contarino MF _et al_: DYT6 dystonia: mutation screening, phenotype,

and response to deep brain stimulation. _Mov Disord_ 2010; 25: 2420–2427. Article  Google Scholar  * Houlden H, Schneider SA, Paudel R _et al_: THAP1 mutations (DYT6) are an additional cause

of early-onset dystonia. _Neurology_ 2010; 74: 846–850. Article  CAS  Google Scholar  * Söhn AS, Glockle N, Doetzer AD _et al_: Prevalence of THAP1 sequence variants in German patients with

primary dystonia. _Mov Disord_ 2010; 25: 1982–1986. Article  Google Scholar  * Xiao J, Zhao Y, Bastian RW _et al_: Novel THAP1 sequence variants in primary dystonia. _Neurology_ 2010; 74:

229–238. Article  CAS  Google Scholar  * Zittel S, Moll CK, Bruggemann N _et al_: Clinical neuroimaging and electrophysiological assessment of three DYT6 dystonia families. _Mov Disord_

2010; 25: 2405–2412. Article  Google Scholar  * Cheng FB, Wan XH, Feng JC, Wang L, Yang YM, Cui LY : Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China. _Eur J

Neurol_ 2011; 18: 497–503. Article  CAS  Google Scholar  * De Carvalho Aguiar P, Fuchs T, Borges V _et al_: Screening of Brazilian families with primary dystonia reveals a novel THAP1

mutation and a _de novo_ TOR1A GAG deletion. _Mov Disord_ 2010; 25: 2854–2857. Article  Google Scholar  * Blanchard A, Roubertie A, Simonetta-Moreau M _et al_: Singular DYT6 phenotypes in

association with new THAP1 frameshift mutations. _Mov Disord_ 2011; e-pub ahead of print 25 April 2011. * Osmanovic A, Dendorfer A, Erogullari A _et al_: Truncating mutations in THAP1 define

the nuclear localization signal. _Mov Disord_ 2011; e-pub ahead of print 14 April 2011. * Adzhubei IA, Schmidt S, Peshkin L _et al_: A method and server for predicting damaging missense

mutations. _Nat Methods_ 2010; 7: 248–249. Article  CAS  Google Scholar  * Ng PC, Henikoff S : SIFT: predicting amino acid changes that affect protein function. _Nucleic Acids Res_ 2003; 31:

3812–3814. Article  CAS  Google Scholar  * Campagne S, Saurel O, Gervais V, Milon A : Structural determinants of specific DNA-recognition by the THAP zinc finger. _Nucleic Acids Res_ 2010;

38: 3466–3476. Article  CAS  Google Scholar  * Schneider SA, Ramirez A, Shafiee K _et al_: Homozygous THAP1 mutations as cause of early-onset generalized dystonia. _Mov Disord_ 2011; 26:

858–861. Article  Google Scholar  * Groen JL, Yildirim E, Ritz K _et al_: THAP1 mutations are infrequent in spasmodic dysphonia. _Mov Disord_ 2011; e-pub ahead of print 29 April 2011. Google

Scholar  * Xiao J, Zhao Y, Bastian RW _et al_: The c.-237_236GA&gt;TT THAP1 sequence variant does not increase risk for primary dystonia. _Mov Disord_ 2011; 26: 549–553. Article  Google

Scholar  Download references ACKNOWLEDGEMENTS This study was supported by governmental and institutional funding, ie by a grant from the Deutsche Forschungsgemeinschaft (to KL, SAS, and

FJK; LO 1555/3-1), the Volkswagen Foundation (Lichtenberg Grant to CK), the Hermann and Lilly Schilling Foundation (to CK), and the Else Kröner Fresenius Foundation (to AAK; EKMS). AUTHOR

INFORMATION Author notes * Katja Lohmann and Nils Uflacker: These authors contributed equally to this work. AUTHORS AND AFFILIATIONS * Section of Clinical and Molecular Neurogenetics at the

Department of Neurology, University of Lübeck, Lübeck, Germany Katja Lohmann, Nils Uflacker, Thora Lohnau, Susen Winkler, Susanne A Schneider, Christine Klein & Norbert Brüggemann *

Institute of Human Genetics, University of Lübeck, Lübeck, Germany Alev Erogullari, Alma Osmanovic & Frank J Kaiser * Institute of Experimental and Clinical Pharmacology and Toxicology,

University of Lübeck, Lübeck, Germany Andreas Dendorfer * Walter Brendel Centre of Experimental Medicine, Ludwig-Maximilians-University Munich, Munich, Germany Andreas Dendorfer * Institute

of Neurology, CCS, Belgrade, Serbia Marina Svetel & Vladimir Kostic * Department of Neurology, Hospital Kassel, Kassel, Germany Andreas Ferbert * Department of Neurology, University

Medical Centre Hamburg-Eppendorf, Hamburg, Germany Simone Zittel, Alexander Münchau & Andreas Kupsch * Department of Neurology, Neurosurgery and Neuroradiology, Charité University

Medicine Berlin, Berlin, Germany Andrea A Kühn * Institute of Music Physiology and Musicians’ Medicine, Hanover University of Music, Drama and Media, Hanover, Germany Alexander Schmidt &

 Eckart Altenmüller * Department of Neurology, University of Rostock, Rostock, Germany Christoph Kamm & Matthias Wittstock * Movement Disorders Center, Toronto Western Hospital,

University of Toronto, University Health Network, Toronto, Ontario, Canada Elena Moro * Department of Neurology, Christian Albrecht University Kiel, Kiel, Germany Jens Volkmann Authors *

Katja Lohmann View author publications You can also search for this author inPubMed Google Scholar * Nils Uflacker View author publications You can also search for this author inPubMed 

Google Scholar * Alev Erogullari View author publications You can also search for this author inPubMed Google Scholar * Thora Lohnau View author publications You can also search for this

author inPubMed Google Scholar * Susen Winkler View author publications You can also search for this author inPubMed Google Scholar * Andreas Dendorfer View author publications You can also

search for this author inPubMed Google Scholar * Susanne A Schneider View author publications You can also search for this author inPubMed Google Scholar * Alma Osmanovic View author

publications You can also search for this author inPubMed Google Scholar * Marina Svetel View author publications You can also search for this author inPubMed Google Scholar * Andreas

Ferbert View author publications You can also search for this author inPubMed Google Scholar * Simone Zittel View author publications You can also search for this author inPubMed Google

Scholar * Andrea A Kühn View author publications You can also search for this author inPubMed Google Scholar * Alexander Schmidt View author publications You can also search for this author

inPubMed Google Scholar * Eckart Altenmüller View author publications You can also search for this author inPubMed Google Scholar * Alexander Münchau View author publications You can also

search for this author inPubMed Google Scholar * Christoph Kamm View author publications You can also search for this author inPubMed Google Scholar * Matthias Wittstock View author

publications You can also search for this author inPubMed Google Scholar * Andreas Kupsch View author publications You can also search for this author inPubMed Google Scholar * Elena Moro

View author publications You can also search for this author inPubMed Google Scholar * Jens Volkmann View author publications You can also search for this author inPubMed Google Scholar *

Vladimir Kostic View author publications You can also search for this author inPubMed Google Scholar * Frank J Kaiser View author publications You can also search for this author inPubMed 

Google Scholar * Christine Klein View author publications You can also search for this author inPubMed Google Scholar * Norbert Brüggemann View author publications You can also search for

this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Katja Lohmann. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no conflict of interest. RIGHTS AND

PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Lohmann, K., Uflacker, N., Erogullari, A. _et al._ Identification and functional analysis of novel _THAP1_

mutations. _Eur J Hum Genet_ 20, 171–175 (2012). https://doi.org/10.1038/ejhg.2011.159 Download citation * Received: 18 May 2011 * Revised: 06 July 2011 * Accepted: 12 July 2011 * Published:

17 August 2011 * Issue Date: February 2012 * DOI: https://doi.org/10.1038/ejhg.2011.159 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get

shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative KEYWORDS * dystonia

* THAP1 * mutation * DNA binding * phenotype–genotype